|
시장보고서
상품코드
2018389
저온 플라즈마 시장 규모, 점유율, 동향 분석 : 압력별, 용도별, 지역별, 부문별 예측(2026-2033년)Cold Plasma Market Size, Share & Trends Analysis Report By Pressure, By Application (Wound Healing, Blood Coagulation, Dentistry, Cancer Treatment, Other Medical Applications), By Region, And Segment Forecasts, 2026 - 2033 |
||||||
저온 플라즈마 시장 요약
세계의 저온 플라즈마(저온 플라즈마) 시장 규모는 2025년에 1억 6,780만 달러로 추계되며, 2033년까지 4억 9,590만 달러에 달할 것으로 예측되고 있으며, 2026-2033년에 CAGR 14.6%로 성장할 것으로 전망되고 있습니다.
이러한 성장은 의료 산업 전반의 발전으로 인해 환자 치료 절차를 개선하고, 안전하고 비침습적인 치료를 위한 첨단 기술에 대한 수요가 증가하고 있기 때문입니다.
또한 저온 플라즈마 기술은 암 치료, 살균, 상처 치유 등의 용도를 향상시켜 시장 성장을 크게 견인하고 있습니다. 비평형 플라즈마라고도 불리는 저온 플라즈마는 구성 요소의 온도에 현저한 차이가 있는 부분적으로 이온화된 기체입니다. 이는 기체에 에너지를 공급하여 생성되며, 고온 플라즈마와 같은 유해한 영향 없이 의료 시술, 살균, 식품 안전 등 다양한 용도에 유용한 반응성 종을 생성합니다.
미시간 대학의 연구에 따르면 저온 플라즈마는 공기 중의 위험한 바이러스를 제거하는 가장 효과적인 솔루션입니다. 비열 플라즈마는 단 몇 분의 1초 만에 바이러스의 최대 99%를 제거할 수 있습니다. 이를 통해 의사들이 저온 플라즈마 기술을 사용하여 호흡기 질환 환자를 치료할 수 있는 기회가 생기고 있습니다.
섬유, 식품 안전, 의료 분야 등 다양한 산업에서의 용도 확대가 시장 성장에 크게 기여하고 있습니다. 또한 지속가능하고 효율적인 처리 기술에 대한 수요 증가와 식품 살균 및 의료 치료 분야의 혁신이 이러한 성장을 더욱 촉진하고 있습니다. 또한 유해한 화학물질을 사용하지 않는 친환경 솔루션을 제공하는 대기압 저온 플라즈마 기술의 발전도 시장을 지원하고 있으며, 다양한 산업에 대한 매력을 높이고 있습니다.
의료시설이 감염 관리 및 멸균을 위한 효과적인 솔루션을 찾고 있는 가운데 병원내 감염(HAI) 발생률의 증가는 저온 플라즈마 시장의 중요한 촉진요인으로 작용하고 있습니다. 예를 들어 세계보건기구(WHO)에 따르면 HAI는 전 세계에서 매년 수억 명의 환자에게 영향을 미치며, 이환율 증가, 입원 기간 연장, 의료비 상승으로 이어지고 있습니다. 미국 질병통제예방센터(CDC)의 추산에 따르면 미국에서만 특정 날 병원 환자 약 31명 중 1명이 적어도 한 가지 이상의 HAI에 걸리며, 이는 연간 약 9만 9,000명의 사망에 관여하는 것으로 추정되고 있습니다.
병원내 감염(HAI)의 증가는 저온 플라즈마 시장의 성장을 크게 촉진하고 있습니다. 저온 플라즈마 기술은 효과적인 항균 특성으로 인해 점점 더 인정받고 있으며, 의료 현장의 감염 관리 및 멸균을 위한 귀중한 솔루션이 되고 있습니다. 병원이 HAI를 줄이고 환자 안전을 개선하기 위해 노력하는 가운데, 저온 플라즈마와 같은 혁신적인 기술에 대한 수요는 계속 증가하고 있습니다. 예를 들어 세계보건기구(WHO)의 '감염 예방 및 관리에 관한 세계 보고서(2024년)'에 따르면 급성기 병원에 입원 중인 환자 100명당 고소득 국가(HIC)에서는 7명, 저소득 국가(LMIC)에서는 15명이 입원 중 최소 한 가지 이상의 HAI에 감염된 것으로 나타났습니다.
자주 묻는 질문
목차
제1장 분석 방법·범위
제2장 개요
제3장 저온 플라즈마 시장 : 변동 요인·동향·범위
제4장 저온 플라즈마 시장 : 압력별 추정·동향 분석
제5장 저온 플라즈마 시장 : 용도별 추정·동향 분석
제6장 저온 플라즈마 시장 : 지역별 추정·동향 분석
제7장 경쟁 구도
KSA 26.05.14Cold Plasma Market Summary
The global cold plasma market size was estimated at USD 167.8 million in 2025 and is projected to reach USD 495.9 million by 2033, growing at a CAGR of 14.6% from 2026 to 2033. This growth is attributed to the overall development of the healthcare industry, which has increased the demand for advanced technologies to enhance patient treatment procedures and make them safe and non-invasive.
In addition, cold plasma technology enhances applications such as cancer treatment, sterilization, and wound healing, driving the market's growth significantly. Cold plasma, also known as non-equilibrium plasma, is a partially ionized gas in which the temperatures of its constituents differ significantly. It is generated by supplying energy to gases, creating reactive species useful in various applications, including medical treatments, sterilization, and food safety, without the harmful effects of high-temperature plasmas.
According to research by the University of Michigan, cold plasma is the most effective solution for removing dangerous airborne viruses. Non-thermal plasma can remove up to 99% of the virus in fractions of a second. This creates opportunities for doctors to treat patients with breathing problems using cold plasma technologies.
Increasing applications across various industries, including textiles, food safety, and medical sectors, significantly contribute to market growth. In addition, the rising demand for sustainable and efficient processing technologies, alongside innovations in food decontamination and medical treatments, further fuels this growth. Furthermore, the market is supported by advancements in atmospheric cold plasma technology, which offers eco-friendly solutions without harmful chemicals, enhancing its attractiveness to diverse industries.
The rising incidence of hospital-acquired infections (HAIs) is a critical driver of the cold plasma market, as healthcare facilities seek effective solutions for infection control and sterilization. For instance, according to the World Health Organization (WHO), HAIs affect hundreds of millions of patients worldwide each year, leading to increased morbidity, extended hospital stays, and higher healthcare costs. In the United States alone, the Centers for Disease Control and Prevention (CDC) estimates that about 1 in 31 hospital patients has at least one HAI on any given day, contributing to approximately 99,000 deaths annually.
Rising cases of hospital-acquired infections (HAIs) are significantly driving the growth of the cold plasma market. Cold plasma technology is increasingly recognized for its effective antimicrobial properties, making it a valuable solution for infection control and sterilization in healthcare settings. As hospitals strive to reduce HAIs and enhance patient safety, the demand for innovative technologies like cold plasma continues to rise. For instance, according to the Global Report on Infection Prevention and Control (2024) by the World Health Organization (WHO), out of every 100 patients in acute-care hospitals, 7 patients in high-income countries (HICs) and 15 patients in low-income countries (LMICs) acquired at least one HAI during their hospital stay.
Global Cold Plasma Market Report Segmentation
This report forecasts revenue growth at global, regional, and country levels and analyzes the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global cold plasma market report based on pressure, application, and region.
- Pressure Outlook (Revenue, USD Million, 2021 - 2033)
- Low-Pressure Cold Plasma
- Atmospheric Pressure Cold Plasma
- Application Outlook (Revenue, USD Million, 2021 - 2033)
- Wound Healing
- Blood Coagulation
- Dentistry
- Cancer Treatment
- Other Medical Applications
- Regional Outlook (Revenue, USD Million, 2021 - 2033)
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- UK
- France
- Italy
- Spain
- Denmark
- Sweden
- Norway
- Asia Pacific
- China
- Japan
- India
- South Korea
- Australia
- Thailand
- Latin America
- Brazil
- Argentina
- Middle East and Africa (MEA)
- Saudi Arabia
- UAE
- South Africa
- Kuwait
Table of Contents
Chapter 1. Methodology and Scope
- 1.1. Market Segmentation and Scope
- 1.2. Market Definitions
- 1.3. Research Methodology
- 1.3.1. Information Procurement
- 1.3.2. Information or Data Analysis
- 1.3.3. Market Formulation & Data Visualization
- 1.3.4. Data Validation & Publishing
- 1.4. Research Scope and Assumptions
- 1.4.1. List of Data Sources
Chapter 2. Executive Summary
- 2.1. Market Outlook
- 2.2. Segment Outlook
- 2.3. Competitive Insights
Chapter 3. Cold Plasma Market Variables, Trends, & Scope
- 3.1. Market Introduction/Lineage Outlook
- 3.2. Market Size and Growth Prospects (USD Million)
- 3.3. Market Dynamics
- 3.3.1. Market Drivers Analysis
- 3.3.2. Market Restraints Analysis
- 3.4. Cold Plasma Market Analysis Tools
- 3.4.1. Porter's Analysis
- 3.4.1.1. Bargaining power of the suppliers
- 3.4.1.2. Bargaining power of the buyers
- 3.4.1.3. Threats of substitution
- 3.4.1.4. Threats from new entrants
- 3.4.1.5. Competitive rivalry
- 3.4.2. PESTEL Analysis
- 3.4.2.1. Political landscape
- 3.4.2.2. Economic and Social landscape
- 3.4.2.3. Technological landscape
- 3.4.2.4. Environmental landscape
- 3.4.2.5. Legal landscape
- 3.4.1. Porter's Analysis
Chapter 4. Cold Plasma Market: Pressure Estimates & Trend Analysis
- 4.1. Segment Dashboard
- 4.2. Global Cold Plasma Market: Pressure Movement Analysis, 2025 & 2033 (USD Million)
- 4.3. Low-Pressure Cold Plasma
- 4.3.1. Low-Pressure Cold Plasma Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 4.4. Atmospheric Pressure Cold Plasma
- 4.4.1. Atmospheric Pressure Cold Plasma Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 5. Cold Plasma Market: Application Estimates & Trend Analysis
- 5.1. Segment Dashboard
- 5.2. Cold Plasma Market: Application Movement Analysis, 2025 & 2033 (USD Million)
- 5.3. Wound Healing
- 5.3.1. Wound Healing Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 5.4. Blood Coagulation
- 5.4.1. Blood Coagulation Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 5.5. Dentistry
- 5.5.1. Dentistry Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 5.6. Cancer Treatment
- 5.6.1. Cancer Treatment Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 5.7. Other Medical Applications
- 5.7.1. Other Medical Applications Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 6. Cold Plasma Market: Regional Estimates & Trend Analysis
- 6.1. Cold Plasma Market Share, By Region, 2025 & 2033 (USD Million)
- 6.2. North America
- 6.2.1. North America Cold Plasma Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.2.2. U.S.
- 6.2.2.1. U.S. Cold Plasma Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.2.3. Canada
- 6.2.3.1. Canada Cold Plasma Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.2.4. Mexico
- 6.2.4.1. Mexico Cold Plasma Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.3. Europe
- 6.3.1. Europe Cold Plasma Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.3.2. UK
- 6.3.2.1. UK Cold Plasma Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.3.3. Germany
- 6.3.3.1. Germany Cold Plasma Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.3.4. France
- 6.3.4.1. France Cold Plasma Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.3.5. Italy
- 6.3.5.1. Italy Cold Plasma Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.3.6. Spain
- 6.3.6.1. Spain Cold Plasma Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.3.7. Denmark
- 6.3.7.1. Denmark Cold Plasma Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.3.8. Sweden
- 6.3.8.1. Sweden Cold Plasma Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.3.9. Norway
- 6.3.9.1. Norway Cold Plasma Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.4. Asia Pacific
- 6.4.1. Asia Pacific Cold Plasma Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.4.2. China
- 6.4.2.1. China Cold Plasma Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.4.3. Japan
- 6.4.3.1. Japan Cold Plasma Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.4.4. India
- 6.4.4.1. India Cold Plasma Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.4.5. South Korea
- 6.4.5.1. South Korea Cold Plasma Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.4.6. Australia
- 6.4.6.1. Australia Cold Plasma Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.4.7. Thailand
- 6.4.7.1. Thailand Cold Plasma Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.5. Latin America
- 6.5.1. Latin America Cold Plasma Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.5.2. Brazil
- 6.5.2.1. Brazil Cold Plasma Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.5.3. Argentina
- 6.5.3.1. Argentina Cold Plasma Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.6. Middle East and Africa
- 6.6.1. Middle East and Africa Cold Plasma Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.6.2. Saudi Arabia
- 6.6.2.1. Saudi Arabia Cold Plasma Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.6.3. UAE
- 6.6.3.1. UAE Cold Plasma Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.6.4. South Africa
- 6.6.4.1. South Africa Cold Plasma Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.6.5. Kuwait
- 6.6.5.1. Kuwait Cold Plasma Market Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 7. Competitive Landscape
- 7.1. Recent Developments & Impact Analysis by Key Market Participants
- 7.2. Company Categorization
- 7.3. Company Heat Map Analysis
- 7.4. Company Profiles
- 7.4.1. Apyx Medical.
- 7.4.1.1. Participant's Overview
- 7.4.1.2. Financial Performance
- 7.4.1.3. Product Benchmarking
- 7.4.1.4. Recent Developments/ Strategic Initiatives
- 7.4.2. Neoplas med GmbH
- 7.4.2.1. Participant's Overview
- 7.4.2.2. Financial Performance
- 7.4.2.3. Product Benchmarking
- 7.4.2.4. Recent Developments/ Strategic Initiatives
- 7.4.3. Adtec Healthcare Limited
- 7.4.3.1. Participant's Overview
- 7.4.3.2. Financial Performance
- 7.4.3.3. Product Benchmarking
- 7.4.3.4. Recent Developments/ Strategic Initiatives
- 7.4.4. Terraplasma GmbH.
- 7.4.4.1. Participant's Overview
- 7.4.4.2. Financial Performance
- 7.4.4.3. Product Benchmarking
- 7.4.4.4. Recent Developments/ Strategic Initiatives
- 7.4.5. CINOGY System GmbH;
- 7.4.5.1. Participant's Overview
- 7.4.5.2. Financial Performance
- 7.4.5.3. Product Benchmarking
- 7.4.5.4. Recent Developments/ Strategic Initiatives
- 7.4.6. Plasmacure.
- 7.4.6.1. Participant's Overview
- 7.4.6.2. Financial Performance
- 7.4.6.3. Product Benchmarking
- 7.4.6.4. Recent Developments/ Strategic Initiatives
- 7.4.7. Relyon Plasma GmbH.
- 7.4.7.1. Participant's Overview
- 7.4.7.2. Financial Performance
- 7.4.7.3. Product Benchmarking
- 7.4.7.4. Recent Developments/ Strategic Initiatives
- 7.4.8. US Medical Innovations
- 7.4.8.1. Participant's Overview
- 7.4.8.2. Financial Performance
- 7.4.8.3. Product Benchmarking
- 7.4.8.4. Recent Developments/ Strategic Initiatives
- 7.4.1. Apyx Medical.
